Anzeige
Mehr »
Freitag, 07.11.2025 - Börsentäglich über 12.000 News
Kanadas neuer Technologie-Champion: Telescope erhält bis zu 3,36 Mio. $ staatliche Förderung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 870513 | ISIN: US7493604000 | Ticker-Symbol:
NASDAQ
06.11.25 | 21:57
22,200 US-Dollar
-4,93 % -1,150
1-Jahres-Chart
RCM TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
RCM TECHNOLOGIES INC 5-Tage-Chart
GlobeNewswire (Europe)
1 Leser
Artikel bewerten:
(0)

RCM Technologies, Inc. Announces Third Quarter Results

PENNSAUKEN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of solutions designed to enhance the operational performance of its customers through the deployment of advanced engineering, specialty health care, and information technology services, today announced financial results for the thirteen and thirty-nine weeks ended September 27, 2025.

RCM Technologies reported revenue of $70.3 million for the thirteen weeks ended September 27, 2025 (the current quarter), an increase of 16.4% compared to $60.4 million for the thirteen weeks ended September 28, 2024 (the comparable prior quarter). Gross profit was $19.4 million for the current quarter, an 8.8% increase compared to $17.8 million for the comparable prior quarter. The Company experienced GAAP net income of $2.3 million, or $0.30 per diluted share, for the current quarter compared to $2.7 million, or $0.35 per diluted share, for the comparable prior quarter. The Company experienced adjusted EBITDA (non-GAAP) of $5.5 million for the current quarter, as compared to $5.6 million for the comparable prior quarter. The Company experienced adjusted net income of $0.42 per diluted share (non-GAAP) for both quarters presented.

RCM Technologies reported revenue of $232.9 million for the thirty-nine weeks ended September 27, 2025 (the current period), an increase of 15.6% compared to $201.5 million for the thirty-nine weeks ended September 28, 2024 (the comparable prior-year period). Gross profit was $63.7 million for the current period, a 9.4% increase compared to $58.2 million for the comparable prior-year period. The Company experienced GAAP net income of $10.2 million, or $1.34 per diluted share, for the current period compared to $10.5 million, or $1.31 per diluted share, for the comparable prior-year period. The Company experienced adjusted EBITDA (non-GAAP) of $21.4 million for the current period, as compared to $19.6 million for the comparable prior-year period. The Company experienced $1.73 of adjusted net income per diluted share (non-GAAP) for the current period as compared to $1.54 for the comparable prior-year period, an increase of 12.3%.

Bradley Vizi, Executive Chairman of RCM Technologies, commented, "As we exit our seasonal third quarter, we are entering the fourth quarter from a position of strength, demonstrating record 2026 Engineering backlog as of the end of October and continued momentum in Healthcare."

Kevin Miller, Chief Financial Officer of RCM Technologies, commented, "We expect our fourth quarter will yield our highest quarterly gross profit and adjusted EBITDA in fiscal 2025, and we are excited about our momentum heading into 2026."

Conference Call
On Thursday, November 6, 2025, RCM Technologies will host a conference call to discuss these results. The call will begin at 11:30 a.m. Eastern Time. The dial-in number is (888) 272-8703.

About RCM
RCM Technologies (NasdaqGM: RCMT) is a business and technology solutions provider with world-class talent in key market segments. We help design, build, and enable the Industries of Tomorrow, Today. Operating at the intersection of resources, critical infrastructure and modernization of industries, RCM is a provider of services in Health Care, Engineering, Aerospace & Defense, Process & Industrial, Life Sciences and Data & Solutions. www.rcmt.com.

The statements contained in this release that are not purely historical are forward-looking statements within the Private Securities Litigation Reform Act of 1995. They are subject to various risks, uncertainties, and other factors that could cause the Company's actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may," "will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should," "are confident" or similar expressions. In addition, statements that are not historical should also be considered forward-looking statements. These statements are based on assumptions that we have made in light of our experience in the industry, and our perceptions of historical trends, current conditions, expected future developments, and other factors we believe are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to demand for the Company's services, expectations regarding our future revenues and other financial results, such as cash flows, our pipeline, and potential project wins, and our expectations for investment and growth in our business. Such statements are based on current expectations that involve several known and unknown risks, uncertainties, and other factors, which may cause actual events to be materially different from those expressed or implied by such forward-looking statements. Risk, uncertainties, and other factors may emerge from time to time that could cause the Company's actual results to differ from those indicated by the forward-looking statements. Investors are directed to consider such risks, uncertainties, and other factors described in documents filed by the Company with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company assumes no obligation (and expressly disclaims any such obligation) to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.

Tables to Follow

RCM Technologies, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In Thousands, Except Share and Per Share Amounts)
Thirteen Weeks Ended
September 27,
2025
September 28,
2024
Revenue$70,289 $60,365
Cost of services50,879 42,524
Gross profit19,410 17,841
Selling, general and administrative14,933 13,018
Depreciation and amortization of property and equipment539 393
Amortization of acquired intangible assets- 45
Operating income3,938 4,385
Other expense, net614 619
Income before income taxes3,324 3,766
Income tax expense1,065 1,020
Net income$2,259 $2,746
Diluted net earnings per share data$0.30 $0.35
Diluted weighted average shares outstanding7,614,695 7,789,446
Thirty-Nine Weeks Ended
September 27,
2025
September 28,
2024
Revenue$232,928 $201,468
Cost of services169,263 143,259
Gross profit63,665 58,209
Selling, general and administrative45,179 40,762
Depreciation and amortization of property and equipment1,364 1,012
Amortization of acquired intangible assets- 136
Potential stock issuance and financial transactions- 259
Operating income17,122 16,040
Other expense, net2,241 1,619
Income before income taxes14,881 14,421
Income tax expense4,651 3,961
Net income$10,230 $10,460
Diluted net earnings per share data$1.34 $1.31
Diluted weighted average shares outstanding7,656,929 7,990,238

RCM Technologies, Inc.
Supplemental Operating Results on a Non-GAAP Basis
(Unaudited)
(In Thousands, Except Per Share Amounts)

The following non-GAAP measures, which adjust for the categories of expenses described below, are non-GAAP financial measures. Our management believes that these non-GAAP financial measures ("Adjusted operating income," "EBITDA," "Adjusted EBITDA," "Adjusted net income" and "Adjusted diluted net earnings per share") are useful information for investors, shareholders, and other stakeholders of our Company in gauging our results of operations on an ongoing basis and to enhance investors' overall understanding of our current financial performance and period-to-period comparisons. Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share should not be considered alternatives to operating income or net income, as the case may be, as an indicator of performance. In addition, Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share do not take into account changes in certain assets and liabilities and interest and income taxes that can affect cash flows. We do not intend the presentation of these non-GAAP measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP. These non-GAAP measures should be read-only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

The following unaudited table presents the Company's GAAP operating income and GAAP net income and the corresponding adjustments used to calculate Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share for the thirteen and thirty-nine weeks ended September 27, 2025 and September 28, 2024.

Thirteen Weeks Ended Thirty-Nine Weeks Ended
September 27,
2025
September 28,
2024
September 27,
2025
September 28,
2024
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
GAAP operating income$3,938 $4,385 $17,122 $16,040
Adjustments
Potential stock issuance and financing transactions- - - 259
Equity compensation1,033 767 2,939 2,154
Adjusted operating income (non-GAAP)$4,971 $5,152 $20,061 $18,453
GAAP net income$2,259 $2,746 $10,230 $10,460
Income tax expense1,065 1,020 4,651 3,961
Interest expense, net584 492 1,885 1,551
Depreciation of property and equipment539 393 1,364 1,012
Amortization of acquired intangible assets- 45 - 136
EBITDA (non-GAAP)$4,447 $4,696 $18,130 $17,120
Adjustments
Potential stock issuance and financing transactions- - - 259
Loss on foreign currency transactions30 127 356 68
Equity compensation1,033 767 2,939 2,154
Adjusted EBITDA (non-GAAP)$5,510 $5,590 $21,425 $19,601
RCM Technologies, Inc.
Supplemental Operating Results on a Non-GAAP Basis (Continued)
(Unaudited)
(In Thousands)
Thirteen Weeks Ended Thirty-Nine Weeks Ended
September 27,
2025
September 28,
2024
September 27,
2025
September 28,
2024
(Unaudited) (Unaudited) (Unaudited) (Unaudited)
GAAP net income$2,259 $2,746 $10,230 $10,460
Adjustments
Potential stock issuance and financing transactions- - - 259
Loss on foreign currency transactions30 127 356 68
Equity compensation1,033 767 2,939 2,154
Tax impact from normalized rate(119)(238)(257)(603)
Adjusted net income (non-GAAP)$3,203 $3,402 $13,268 $12,338
GAAP diluted net earnings per share$0.30 $0.35 $1.34 $1.31
Adjustments
Potential stock issuance and financing transactions- - - $0.03
Loss on foreign currency transactions$0.01 $0.01 $0.05 $0.01
Equity compensation$0.13 $0.09 $0.38 $0.27
Tax impact from normalized rate($0.02
)($0.03
)($0.04
)($0.08
)
Adjusted diluted net earnings per share (non-GAAP)$0.42 $0.42 $1.73 $1.54
RCM Technologies, Inc.
Summary of Selected Income Statement Data
(Unaudited)
(In Thousands)
Thirteen Weeks Ended September 27, 2025
Specialty
Health Care
Engineering Life Sciences,
Data and
Solutions


Consolidated
Revenue$30,000 $31,419 $8,870 $70,289
Cost of services21,010 24,507 5,362 50,879
Gross profit8,990 6,912 3,508 19,410
Gross profit margin30.0%22.0%39.5%27.6%
Thirteen Weeks Ended September 28, 2024
Specialty
Health Care
Engineering Life Sciences,
Data and
Solutions


Consolidated
Revenue$26,554 $24,167 $9,644 $60,365
Cost of services18,271 18,273 5,980 42,524
Gross profit8,283 5,894 3,664 17,841
Gross profit margin31.2%24.4%38.0%29.6%
Thirty-Nine Weeks Ended September 27, 2025
Specialty
Health Care
Engineering Life Sciences,
Data and
Solutions


Consolidated
Revenue$116,105 $90,082 $26,741 $232,928
Cost of services82,634 70,496 16,133 169,263
Gross profit33,471 19,586 10,608 63,665
Gross profit margin28.8%21.7%39.7%27.3%
Thirty-Nine Weeks Ended September 28, 2024
Specialty
Health Care
Engineering Life Sciences,
Data and
Solutions


Consolidated
Revenue$101,668 $70,180 $29,620 $201,468
Cost of services71,672 52,818 18,769 143,259
Gross profit29,996 17,362 10,851 58,209
Gross profit margin29.5%24.7%36.6%28.9%
RCM Technologies, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In Thousands, Except Share Amounts)
September 27, December 28,
2025 2024
(Unaudited)
Current assets:
Cash and cash equivalents
$1,309 $4,729
Accounts receivable and contract assets, net of provision for credit losses of $1,541 at September 27, 2025 and $1,570 at December 28, 2024
83,243 77,960
Transit accounts receivable
6,215 7,315
Prepaid expenses and other current assets
4,160 7,034
Total current assets
94,927 97,038
Property and equipment, net7,624 7,368
Other assets:
Deposits
278 230
Deferred tax assets, foreign
131 120
Goodwill
22,147 22,147
Operating right of use asset
4,708 5,174
Total other assets
27,264 27,671
Total assets
$129,815 $132,077
Current liabilities:
Accounts payable and accrued expenses
$13,080 $13,369
Transit accounts payable
13,440 23,870
Accrued payroll and related costs
12,795 9,929
Finance lease payable
889 698
Income taxes payable
247 346
Operating lease liability
1,121 1,046
Contingent consideration from acquisitions
212 212
Deferred revenue
6,230 4,163
Total current liabilities
48,014 53,633
Deferred income taxes, net, domestic4,526 4,526
Finance lease payable, net of current position566 1,112
Operating lease liability, net of current position3,796 4,355
Borrowings under line of credit31,535 34,967
Total liabilities
88,437 98,593
Contingencies (note 15)
Stockholders' equity:
Preferred stock, $1.00 par value; 5,000,000 shares authorized; no shares issued or outstanding
- -
Common stock, $0.05 par value; 40,000,000 shares authorized; 17,948,409 shares issued and 7,410,510 shares outstanding at September 27, 2025 and 17,838,372 shares issued and 7,602,113 shares outstanding at December 28, 2024
898 890
Additional paid-in capital
121,453 118,845
Accumulated other comprehensive loss
(2,757) (2,920)
Retained earnings (accumulated deficit)
4,292 (5,938)
Treasury stock, 10,537,899 shares at September 27, 2025 and 10,236,259 shares at December 28, 2024
(82,508) (77,393)
Total stockholders' equity
41,378 33,484
Total liabilities and stockholders' equity
$129,815 $132,077
RCM Technologies, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In Thousands)
Thirteen Weeks Ended
September 27,
2025
September 28,
2024
Net income$2,259 $2,746
Adjustments to reconcile net income to cash used in operating activities1,825 1,508
Changes in operating assets and liabilities:
Accounts receivable and contract assets515 (9,033)
Prepaid expenses and other current assets(175) 321
Net of transit accounts receivable and payable(7,659) 435
Accounts payable and accrued expenses3,312 (1,445)
Accrued payroll and related costs2,431 1,919
Operating lease liabilities(274) (228)
Income taxes payable(538) 81
Deferred revenue(2,939) (636)
Deposits(19) (12)
Total adjustments(3,521) (7,090)
Net cash (used in) operating activities($1,262
) ($4,344
)
Net cash used in investing activities(498) (522)
Net cash (used in) provided by financing activities(2,379) 4,375
Effect of exchange rate changes on cash and cash equivalents(24) 167
Decrease in cash and cash equivalents($4,163
) ($324
)
Thirty-Nine Weeks Ended
September 27,
2025
September 28,
2024
Net income$10,230
$10,460
Adjustments to reconcile net income to cash used in operating activities5,080 4,200
Changes in operating assets and liabilities:
Accounts receivable and contract assets(5,249) (5,207)
Prepaid expenses and other current assets2,865 (475)
Net of transit accounts receivable and payable(9,330) (311)
Accounts payable and accrued expenses(69) (760)
Accrued payroll and related costs2,860 433
Operating lease liabilities(809) (686)
Income taxes payable(108) (106)
Deferred revenue2,098 161
Deposits(48) 98
Total adjustments(2,710) (2,653)
Net cash provided by operating activities$7,520
$7,807
Net cash used in investing activities(1,398) (1,589)
Net cash used in financing activities(9,471) (9,135)
Effect of exchange rate changes on cash and cash equivalents(71) (211)
Decrease in cash and cash equivalents($3,420
) ($3,128
)
RCM Technologies, Inc.Tel: 856.356.4500Corporate Contacts:
2500 McClellan Avenueinfo@rcmt.comBradley S. Vizi
Pennsauken, NJ 08109www.rcmt.comExecutive Chairman
Kevin D. Miller
Chief Financial Officer

© 2025 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.